Abstract
The discovery and optimization of nonbonded interactions, such as van der Waals interactions, hydrogen bonds, salt bridges and the hydrophobic effect, between small molecule ligands and their receptors is one of the main challenges in rational drug discovery. As the theory of molecular interactions advances more evidence accumulates that nonbonded interactions, such as unconventional hydrogen bonds (X-H Y interactions, where X can be either C, N or O atom and Y can be either an aromatic ring system, O or F atom), contribute to ligand recognition by biological receptors. This review provides an overview of unconventional hydrogen bonds between ligands and their receptors of pharmaceutical relevance by dissecting their structure activity relationships and 3D structural elements. Gaining an understanding of the energetic and the structural properties of unconventional hydrogen bonds in ligand-receptor interactions leads us to the elucidation of their practical significance. Ultimately, this enables us to consciously apply these interactions in hit and lead optimization in rational structure based drug design.
Keywords: Weakly polar interaction, unconventional hydrogen bond, blue-shifting hydrogen bond, N-H...π interaction, O-H...π interaction, π...π interaction, C-H...O interaction, C-H...F-C interaction, N-H...F-C interaction, O-H...F-C interaction
Current Pharmaceutical Design
Title: The Role and Significance of Unconventional Hydrogen Bonds in Small Molecule Recognition by Biological Receptors of Pharmaceutical Relevance
Volume: 13 Issue: 34
Author(s): Gergely Toth, Simeon G. Bowers, Anh P. Truong and Gary Probst
Affiliation:
Keywords: Weakly polar interaction, unconventional hydrogen bond, blue-shifting hydrogen bond, N-H...π interaction, O-H...π interaction, π...π interaction, C-H...O interaction, C-H...F-C interaction, N-H...F-C interaction, O-H...F-C interaction
Abstract: The discovery and optimization of nonbonded interactions, such as van der Waals interactions, hydrogen bonds, salt bridges and the hydrophobic effect, between small molecule ligands and their receptors is one of the main challenges in rational drug discovery. As the theory of molecular interactions advances more evidence accumulates that nonbonded interactions, such as unconventional hydrogen bonds (X-H Y interactions, where X can be either C, N or O atom and Y can be either an aromatic ring system, O or F atom), contribute to ligand recognition by biological receptors. This review provides an overview of unconventional hydrogen bonds between ligands and their receptors of pharmaceutical relevance by dissecting their structure activity relationships and 3D structural elements. Gaining an understanding of the energetic and the structural properties of unconventional hydrogen bonds in ligand-receptor interactions leads us to the elucidation of their practical significance. Ultimately, this enables us to consciously apply these interactions in hit and lead optimization in rational structure based drug design.
Export Options
About this article
Cite this article as:
Toth Gergely, Bowers G. Simeon, Truong P. Anh and Probst Gary, The Role and Significance of Unconventional Hydrogen Bonds in Small Molecule Recognition by Biological Receptors of Pharmaceutical Relevance, Current Pharmaceutical Design 2007; 13 (34) . https://dx.doi.org/10.2174/138161207782794284
DOI https://dx.doi.org/10.2174/138161207782794284 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design Drugs in Newborn Resuscitation: The More We Learn the Least We Use
Current Medicinal Chemistry Tailored Angiogenesis Inhibition in Cancer Therapy: Respecting the Heart to Improve the Net Outcome
Current Signal Transduction Therapy Three-Dimensional Ultrasound in Fetal Size and Growth Assessment
Current Medical Imaging Controlled Drug Delivery Using Microdevices
Current Pharmaceutical Biotechnology A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Current Genomics in Cardiovascular Medicine
Current Genomics The Complex Role of Pro- and Anti-Inflammatory Cytokines in Cysticercosis:Immunological Lessons from Experimental and Natural Hosts
Current Topics in Medicinal Chemistry Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Non-Steroidal Anti-Inflammatory Drugs used as a Treatment Modality in Subarachnoid Hemorrhage
Current Drug Safety Novel Oral Anticoagulants in Peripheral Arterial and Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Noninvasive Monitoring of Intracranial Pressure
Recent Patents on Biomedical Engineering (Discontinued) Oral Anticoagulation in Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Pulmonary Embolism Response Team (PERT) - A New Paradigm for the Treatment of Pulmonary Embolism
Current Pharmaceutical Design Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Post Dural Puncture Headache and Hypertension
Current Hypertension Reviews